Immix Biopharma Inc, a US-based company involved in Tissue Specific Therapeutics for oncology and inflammation, announced on Wednesday that Jane Buchan, PhD is its new director.
Dr Buchan is also a director of Globe Life Inc and AGF Management Ltd. She is chief executive officer of Martlet Asset Management. She has served as CEO of PAAMCO. She started her career at JP Morgan Investment Management in the Capital Markets Group and has been an assistant professor of Finance at the Amos Tuck School of Business at Dartmouth. She has held the position of chairwoman of the board for the Chartered Alternative Investment Analyst Association and is a member of the Advisory Board for the Master of Financial Engineering Program at UCLA Anderson School of Management. She is serving as a trustee of Reed College, Portland, Oregon and University of California Irvine Foundation.
Dr Buchan holds a BA in Economics from Yale University and both a PhD and an MA in Business Economics (Finance) from Harvard University.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886